01 septiembre 2013

JACC. Prognostic Value of Chronic Kidney Disease After Transcatheter Aortic Valve Implantation

Masanori Yamamoto, MD, PhD; Kentaro Hayashida, MD, PhD; Gauthier Mouillet, MD; Thomas Hovasse, MD; Bernard Chevalier, MD; Atsushi Oguri, MD, PhD; Yusuke Watanabe, MD; Jean-Luc Dubois-Randé, MD, PhD; Marie-Claude Morice, MD; Thierry Lefèvre, MD; Emmanuel Teiger, MD, PhD

Objectives: This study sought to assess the influence of chronic kidney disease (CKD) classification on clinical outcomes in patients undergoing transcatheter aortic valve implantation (TAVI).

01 septiembre 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Adjunctive Cilostazol Versus Double-Dose Clopidogrel After Drug-Eluting Stent Implantation. The HOST-ASSURE Randomized Trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis–Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen)

Kyung Woo Park, MD, PhD; Si-Hyuck Kang, MD; Jin Joo Park, MD; Han-Mo Yang, MD, PhD; Hyun-Jae Kang, MD, PhD; Bon-Kwon Koo, MD, PhD; Byoung-Eun Park, MD, PhD; Kwang Soo Cha, MD, PhD; Jay Young Rhew, MD, PhD; Hui-Kyoung Jeon, MD, PhD; Eun Seok Shin, MD, PhD; Ju Hyeon Oh, MD, PhD; Myung-Ho Jeong, MD, PhD; Sanghyun Kim, MD, PhD; Kyung-Kuk Hwang, MD, PhD; Jung-Han Yoon, MD, PhD; Sung Yun Lee, MD, PhD; Tae-Ho Park, MD, PhD; Keon Woong Moon, MD, PhD; Hyuck-Moon Kwon, MD, PhD; In-Ho Chae, MD, PhD; Hyo-Soo Kim, MD, PhD

Objectives: This study sought to test the noninferiority of triple antiplatelet therapy (TAT) versus double-dose clopidogrel dual antiplatelet therapy (DDAT) in patients undergoing percutaneous coronary intervention (PCI).

09 septiembre 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Elevated Levels of Systemic Pentraxin 3 Are Associated With Thin-Cap Fibroatheroma in Coronary Culprit Lesions. Assessment by Optical Coherence Tomography and Intravascular Ultrasound

Seiji Koga, MD; Satoshi Ikeda, MD; Takeo Yoshida, MD; Tomoo Nakata, MD; Masayoshi Takeno, MD; Nobuhito Masuda, PhD; Yuji Koide, MD; Hiroaki Kawano, MD; Koji Maemura, MD

Objectives: This study sought to determine whether systemic levels of pentraxin 3 (PTX3), a novel inflammatory marker, are associated with thin-cap fibroatheroma (TCFA).

01 septiembre 2013

AMERICAN HEART JOURNAL. Change in enrollment patterns, patient selection, and clinical outcomes with the availability of drug-eluting stents in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial

Binita Shah, MD, MS , Vankeepuram S. Srinivas, MBBS, MS , Jiang Lu, MS , Maria M. Brooks, PhD , Eric R. Bates, MD , Zoran S. Nedeljkovic, MD , Jorge Escobedo, MD , Gladwin S. Das, MD , John J. Lopez, MD , Frederick Feit, MD

Background: In the BARI 2D trial, patients with type 2 diabetes and stable coronary artery disease were randomized to prompt revascularization versus intensive medical therapy (IMT). This analysis sought to evaluate how the availability of drug-eluting stents (DESs) has changed practice and outcomes.

01 septiembre 2013

CIRCULATION. Stroke or Transient Ischemic Attack in Patients With Transvenous Pacemaker or Defibrillator and Echocardiographically Detected Patent Foramen Ovale

Christopher V. DeSimone, MD, PhD; Paul A. Friedman, MD; Amit Noheria, MBBS, SM; Nikhil A. Patel, MS; Daniel C. DeSimone, MD; Sami Bdeir, MD; Christopher A. Aakre, MD; Vaibhav R. Vaidya, MBBS; Joshua P. Slusser, BS; David O. Hodge, MS; Michael J. Ackerman, MD, PhD; Alejandro A. Rabinstein, MD; Samuel J. Asirvatham, MD

Background—A patent foramen ovale (PFO) may permit arterial embolization of thrombi that accumulate on the leads of cardiac implantable electronic devices in the right-sided cardiac chambers. We sought to determine whether a PFO increases the risk of stroke/transient ischemic attack (TIA) in patients with endocardial leads.

01 agosto 2013

JACC. Impact of Low Flow on the Outcome of High-Risk Patients Undergoing Transcatheter Aortic Valve Replacement

Florent Le Ven, MD; Mélanie Freeman, MD; John Webb, MD; Marie-Annick Clavel, DVM, PhD; Miriam Wheeler, MD; Éric Dumont, MD; Chris Thompson, MD; Robert De Larochellière, MD; Robert Moss, MD; Daniel Doyle, MD; Henrique B. Ribeiro, MD; Marina Urena, MD; Luis Nombela-Franco, MD; Josep Rodés-Cabau, MD; Philippe Pibarot, DVM, PhD

Objectives: This study sought to assess the impact of baseline left ventricular (LV) outflow, LV ejection fraction (LVEF), and transvalvular gradient on outcomes following transcatheter aortic valve replacement (TAVR) in patients with severe aortic stenosis (AS).

01 septiembre 2013

CIRCULATION. Cost-Effectiveness of Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease and Abnormal Fractional Flow Reserve

William F. Fearon, MD; David Shilane, PhD; Nico H.J. Pijls, MD, PhD; Derek B. Boothroyd, PhD; Pim A.L. Tonino, MD, PhD; Emanuele Barbato, MD, PhD; Peter Jüni, MD; Bernard De Bruyne, MD, PhD; Mark A. Hlatky, MD; on behalf of the Fractional Flow Reserve Versus Angiography for Multivessel Evaluation 2 (FAME 2) Investigators

Background—The Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 2 trial demonstrated a significant reduction in subsequent coronary revascularization among patients with stable angina and at least 1 coronary lesion with a fractional flow reserve ≤0.80 who were randomized to percutaneous coronary intervention (PCI) compared with best medical therapy. The economic and quality-of-life implications of PCI in the setting of an abnormal fractional flow reserve are unknown.

01 agosto 2013

JACC. Clinical Outcomes With Drug-Eluting and Bare-Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction. Evidence From a Comprehensive Network Meta-Analysis

Tullio Palmerini, MD; Giuseppe Biondi-Zoccai, MD; Diego Della Riva, MD; Andrea Mariani, MD; Manel Sabaté, MD; Marco Valgimigli, MD; Giacomo Frati, MD; Elvin Kedhi, MD; Pieter C. Smits, MD; Christoph Kaiser, MD; Philippe Genereux, MD; Soren Galatius, MD; Ajay J. Kirtane, MD, SM; Gregg W. Stone, MD

Objectives: The authors investigated the relative safety and efficacy of different drug-eluting stents (DES) and bare metal stents (BMS) in patients with ST-segment elevation myocardial infarction (STEMI) using a network meta-analysis.

01 septiembre 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Preparatory Balloon Aortic Valvuloplasty During Transcatheter Aortic Valve Implantation for Improved Valve Sizing

Polykarpos C. Patsalis, MD; Fadi Al-Rashid, MD; Till Neumann, MD; Björn Plicht, MD; Heike A. Hildebrandt, MD; Daniel Wendt, MD; Matthias Thielmann, MD; Heinz G. Jakob, MD; Gerd Heusch, MD; Raimund Erbel, MD; Philipp Kahlert, MD

Objectives: This study sought to evaluate whether supra-aortic angiography during preparatory balloon aortic valvuloplasty (BAV) improves valve sizing.

01 agosto 2013

CIRCULATION. Anatomical and Procedural Features Associated With Aortic Root Rupture During Balloon-Expandable Transcatheter Aortic Valve Replacement

Marco Barbanti, MD; Tae-Hyun Yang, MD; Josep Rodès Cabau, MD; Corrado Tamburino, MD; David A. Wood, MD; Hasan Jilaihawi, MD; Phillip Blanke, MD; Raj R. Makkar, MD; Azeem Latib, MD; Antonio Colombo, MD; Giuseppe Tarantini, MD; Rekha Raju, MD; Ronald K. Binder, MD; Giang Nguyen, MD; Melanie Freeman, MD; Henrique B. Ribeiro, MD; Samir Kapadia, MD; James Min, MD; Gudrun Feuchtner, MD; Ronen Gurtvich, MD; Faisal Alqoofi, MD; Marc Pelletier, MD; Gian Paolo Ussia, MD; Massimo Napodano, MD; Fabio Sandoli de Brito Jr, MD; Susheel Kodali, MD; Bjarne L. Norgaard, MD; Nicolaj C. Hansson, MD; Gregor Pache, MD; Sergio J. Canovas, MD; Hongbin Zhang, PhD; Martin B. Leon, MD; John G. Webb, MD; Jonathon Leipsic, MD

Background—Aortic root rupture is a major concern with balloon-expandable transcatheter aortic valve replacement (TAVR). We sought to identify predictors of aortic root rupture during balloon-expandable TAVR by using multidetector computed tomography.

01 julio 2013

JACC. Cause of Death Within 30 Days of Percutaneous Coronary Intervention in an Era of Mandatory Outcome Reporting

Bhuvnesh Aggarwal, MD; Stephen G. Ellis, MD; A. Michael Lincoff, MD; Samir R. Kapadia, MD; Joseph Cacchione, MD; Russell E. Raymond, DO; Leslie Cho, MD; Christopher Bajzer, MD; Ravi Nair, MD; Irving Franco, MD; Conrad Simpfendorfer, MD; E. Murat Tuzcu, MD; Patrick L. Whitlow, MD; Mehdi H. Shishehbor, DO, MPH

Objectives This study sought to ascertain causes of death and the incidence of percutaneous coronary intervention (PCI)-related mortality within 30 days.

01 agosto 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Prospective Randomized Trial of Transthoracic Echocardiography Versus Transesophageal Echocardiography for Assessment and Guidance of Transcatheter Closure of Atrial Septal Defects in Children Using the Amplatzer Septal Occluder

Sergio Bartakian, MD; Howaida G. El-Said, MD, PhD; Beth Printz, MD, PhD; John W. Moore, MD, MPH

Objectives This study sought to determine whether transthoracic echocardiography (TTE) can provide safety and efficacy equivalent to transesophageal echocardiography (TEE) for assessment and guidance of transcatheter atrial septal defect (ASD) closure in pediatric patients.

01 septiembre 2013

AMERICAN HEART JOURNAL. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis

Seiji Habara, MD , Masashi Iwabuchi, MD , Naoto Inoue, MD , Shigeru Nakamura, MD , Ryuta Asano, MD , Shinsuke Nanto, MD , Yasuhiko Hayashi, MD , Nobuo Shiode, MD , Shigeru Saito, MD , Yuji Ikari, MD , Takeshi Kimura, MD , Joji Hosokawa, MD , Masato Nakamura, MD , Jun-ichi Kotani, MD , Ken Kozuma, MD , Kazuaki Mitsudo, MD

Background: The aim of this study was to investigate the efficacy and safety of paclitaxel-coated balloon (PCB) for the treatment of the bare-metal stent restenosis (BMS-ISR) and drug-eluting stent restenosis (DES-ISR).

01 octubre 2013

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Impact of Stent Surface on Thrombogenicity and Vascular Healing. A Comparative Analysis of Metallic and Polymeric Surfaces

Michael J. Eppihimer, PhD, Natalia Sushkova, MD, Jessica L. Grimsby, PhD, Natalia Efimova, BS, Wang Kai, PhD, Steve Larson, BS, Bruce Forsyth, PhD, Barbara A. Huibregtse, DVM, Keith D. Dawkins, MD, Gregory J. Wilson, MD and Juan F. Granada, MD

Background—Emerging drug-eluting stent technologies are evolving toward the elimination of polymeric component used as the method for modulating drug delivery. Although this technological approach seems to be biologically appealing, the impact of durable polymers and metallic stent surfaces on vascular healing remains unclear. In the present study, we aimed to compare the independent effect of a durable polymer and a metallic stent surface on thrombogenicity and endothelial cell coverage using different in vitro and in vivo experimental models.

01 agosto 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Improved Safety and Reduction in Stent Thrombosis Associated With Biodegradable Polymer-Based Biolimus-Eluting Stents Versus Durable Polymer-Based Sirolimus-Eluting Stents in Patients With Coronary Artery Disease. Final 5-Year Report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) Randomized, Noninferiority Trial

Patrick W. Serruys, MD, PhD; Vasim Farooq, MB, ChB; Bindu Kalesan, PhD, MPH; Ton de Vries, MSc; Pawel Buszman, MD, PhD; Axel Linke, MD; Thomas Ischinger, MD; Volker Klauss, MD; Franz Eberli, MD; William Wijns, MD, PhD; Marie Claude Morice, MD; Carlo Di Mario, MD, PhD; Roberto Corti, MD; Diethmar Antoni, MD; Hae Y. Sohn, MD; Pedro Eerdmans, MD, PhD; Tessa Rademaker-Havinga, MSc; Gerrit-Anne van Es, PhD; Bernhard Meier, MD, PhD; Peter Jüni, MD; Stephan Windecker, MD

Objectives: This study sought to report the final 5 years follow-up of the landmark LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) trial.